|
|
Volumn 2, Issue 3, 2001, Pages 238-244
|
|
Leukotrienes in respiratory disease
a
|
|
Author keywords
5 lipoxygenase inhibitors; Cysteinyl leukotriene antagonists; Leuk B4
|
|
Indexed keywords
3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID;
4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLSULFONYL] 3 OXO 4 PHENYLBUTYRIC ACID;
6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE;
7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID;
ACETYLSALICYLIC ACID;
ANTIINFLAMMATORY AGENT;
ARACHIDONATE 12 LIPOXYGENASE;
ARACHIDONATE 15 LIPOXYGENASE;
ARACHIDONATE 5 LIPOXYGENASE;
ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN;
ARACHIDONIC ACID;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
CORTICOSTEROID;
LEUKOTRIENE B4;
LEUKOTRIENE C4;
LEUKOTRIENE D4;
LEUKOTRIENE DERIVATIVE;
LEUKOTRIENE E4;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
LIPOXYGENASE INHIBITOR;
MONTELUKAST;
PEPTIDOLEUKOTRIENE;
PRANLUKAST;
SLOW REACTING SUBSTANCE;
STEROID;
TOMELUKAST;
UNINDEXED DRUG;
VERLUKAST;
ZAFIRLUKAST;
ZILEUTON;
ARACHIDONIC ACID METABOLISM;
ARTICLE;
ASTHMA;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL PRACTICE;
CONTROLLED STUDY;
CYTOKINE PRODUCTION;
DRUG APPROVAL;
DRUG CLASSIFICATION;
DRUG DESIGN;
DRUG EFFICACY;
DRUG INFORMATION;
DRUG MECHANISM;
DRUG POTENTIATION;
DRUG RESEARCH;
HUMAN;
INHALATION TEST;
LONG TERM CARE;
LUNG;
LUNG FUNCTION;
MEDICAL SPECIALIST;
NEUTROPHIL CHEMOTAXIS;
PRIORITY JOURNAL;
RESPIRATORY TRACT DISEASE;
SIDE EFFECT;
SYMPTOMATOLOGY;
|
|
EID: 0035736441
PISSN: 15260550
EISSN: None
Source Type: Journal
DOI: 10.1053/prrv.2001.0146 Document Type: Article |
|
Times cited : (38)
|
|
References (14)
|
